MPM BioImpact, a biotechnology investment firm, agreed to acquire Reunion Neuroscience, a clinical-stage biopharmaceutical company, for $13m. “We believe that this all-cash transaction maximizes value and is in the best interest of our shareholders. We are thrilled that MPM recognizes the value and differentiation of our clinical pipeline and look forward to working with them to bring this transaction to a close for the benefit of Reunion’s shareholders," Greg Mayes, Reunion President and CEO.